	US 12,233,113 B2
	Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency
Tae Kyung Kim, Gyeonggi-do (KR); Young Joo Ahn, Gyeonggi-do (KR); Jung Won Woo, Seoul (KR); Ji-Eun Cha, Seoul (KR); Joan Yoon Ji Lee, Gyeonggi-do (KR); and Woo Ick Jang, Seoul (KR)
Assigned to GENEXINE, INC., Seongnam-si (KR); and HANDOK INC., Seoul (KR)
Appl. No. 16/077,177
Filed by GENEXINE, INC., Gyeonggi-do (KR); and HANDOK INC., Seoul (KR)
PCT Filed Feb. 16, 2017, PCT No. PCT/KR2017/001726 § 371(c)(1), (2) Date Aug. 10, 2018, PCT Pub. No. WO2017/142331, PCT Pub. Date Aug. 24, 2017.
Claims priority of application No. 10-2016-0018695 (KR), filed on Feb. 17, 2016; and application No. 10-2017-0021104 (KR), filed on Feb. 16, 2017.
Prior Publication US 2021/0177945 A1, Jun. 17, 2021
Int. Cl. A61K 38/16 (2006.01); A61K 9/00 (2006.01); A61K 38/18 (2006.01); A61K 38/22 (2006.01); A61K 38/27 (2006.01); A61P 5/06 (2006.01); C07K 14/61 (2006.01)

CPC A61K 38/27 (2013.01) [A61K 9/0019 (2013.01); A61P 5/06 (2018.01)]

4 Claims

1. A method for treating growth hormone deficiency in a human patient in need thereof, comprising

(i) administering a recombinant human growth hormone (hGH) GX-H9 to the human patient once a week at a dosage of 0.1 to 0.3 mg per weight kg of the human patient, or

(ii) administering a recombinant hGH GX-H9 to the patient twice a month at a dosage of 0.1 to 0.4 mg per weight kg of the human patient,

wherein the human patient is an adult, and

wherein the recombinant hGH GX-H9 comprises the amino acid sequence of SEQ ID NO: 1.